Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 18, 2021; 11(12): 503-511
Published online Dec 18, 2021. doi: 10.5500/wjt.v11.i12.503
Solid organ transplantations and COVID-19 disease
Emine Aylin Yılmaz, Öner Özdemir
Emine Aylin Yılmaz, Öner Özdemir, Division of Pediatric Allergy and Immunology, Sakarya University Medical Faculty, Adapazarı 54100, Sakarya, Turkey
Author contributions: Yılmaz EA and Özdemir Ö wrote the mini-review.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Öner Özdemir, MD, Full Professor, Division of Pediatric Allergy and Immunology, Sakarya University Medical Faculty, Adnan Menderes Cad., Adapazarı 54100, Sakarya, Turkey.
Received: July 6, 2021
Peer-review started: July 6, 2021
First decision: July 28, 2021
Revised: August 4, 2021
Accepted: November 14, 2021
Article in press: November 14, 2021
Published online: December 18, 2021
Core Tip

Core Tip: Coronavirus disease 2019 (COVID-19) has not only interrupted the lives of waiting list patients’; it has additionally impacted transplantation policies, transplant surgeries and broken donation chains. Revised guidelines should advise to continue cyclosporine use as an immunosuppressant to the patients during COVID-19 disease excluding some of patients having kidney failure, severe leucopenia or high serum cyclosporine levels.